Welcome to our dedicated page for Becton Dickinson & Co news (Ticker: BDX), a resource for investors and traders seeking the latest updates and insights on Becton Dickinson & Co stock.
Becton, Dickinson and Company (NYSE: BDX) is a global leader in medical technology driving advancements in healthcare through innovative devices, diagnostic solutions, and clinical systems. This page provides real-time updates on BD's latest developments, offering investors and professionals a centralized hub for tracking corporate announcements and industry impact.
Access authoritative information including earnings reports, regulatory milestones, product innovations, and strategic partnerships. Our curated news collection helps stakeholders monitor BD's contributions to medication management, diagnostic testing, and surgical care across 190+ countries.
Key updates cover BD Medical safety-engineered products, BD Life Sciences diagnostic platforms, and BD Interventional surgical technologies. Stay informed about developments in smart medication systems, infectious disease testing, and minimally invasive procedures shaping modern healthcare.
Bookmark this page for ongoing insights into BD's operational updates, leadership changes, and R&D breakthroughs. Verify critical information directly through primary sources while maintaining awareness of market trends in the $600B+ medical technology sector.
BD (Becton, Dickinson and Company) has announced an agreement to acquire Edwards Lifesciences' Critical Care product group for $4.2 billion in cash. This acquisition aims to expand BD's portfolio of smart connected care solutions and enhance its position in advanced monitoring technologies.
Critical Care, a global leader in advanced patient monitoring, generated over $900 million in revenue in 2023 and employs approximately 4,500 people. The acquisition is expected to be immediately accretive to BD's revenue growth, adjusted gross and operating margins, and adjusted earnings per share.
Critical Care will operate as a separate business unit within BD's Medical segment and will continue to be based in Irvine, California, under the leadership of Katie Szyman. The transaction is expected to close by the end of the calendar year, subject to regulatory reviews and closing conditions.
BD plans to fund the acquisition with a combination of $1 billion in cash and $3.2 billion in new debt. The company expects to achieve additional margin expansion and value through cost synergies and efficiencies.
On May 15, 2024, BD (Becton, Dickinson and Company) announced FDA approval for the use of self-collected vaginal specimens for HPV testing when cervical specimens cannot be obtained. This approval allows women to collect samples in various healthcare settings, including non-traditional locales like retail pharmacies and mobile clinics. The BD Onclarity™ HPV Assay, which doesn't require a traditional Pap smear, enhances access to cervical cancer screening, particularly for underserved populations. Around 25% of U.S. women do not receive regular cervical cancer screenings, with higher rates of cervical cancer among Black, Hispanic, and American Indian women. This initiative aims to increase screening acceptance and participation, offering a significant advancement in cervical cancer prevention.
BD reported strong financial results for the second quarter of fiscal 2024, with revenue increasing by 4.6%, GAAP and adjusted EPS growing by 20.9% and 10.8% respectively, and year-to-date cash flow improving significantly. The company raised its full-year adjusted EPS guidance and affirmed organic revenue growth guidance. BD's performance was driven by its diverse portfolio and focus on operational excellence.
The company's recent highlights include increasing domestic production of syringes, launching new products such as automated dispensing cabinet systems and cell sorters, and forming strategic partnerships to enhance healthcare solutions. BD also received recognition for innovation and employee well-being.
BD (Becton, Dickinson and Company) declares a quarterly dividend of $0.95 per common share, payable on June 28, 2024. The indicated annual dividend rate is $3.80 per share.
BD (Becton, Dickinson and Company) will be presenting at the Bank of America Securities Health Care Conference 2024 on May 14, 2024. The presentation will be live-streamed on BD's investor relations website.
FAQ
What is the current stock price of Becton Dickinson & Co (BDX)?
What is the market cap of Becton Dickinson & Co (BDX)?
